Seproxetine

From WikiMD's Wellness Encyclopedia

Seproxetine is a serotonin reuptake inhibitor (SRI) that was being developed by Eli Lilly and Company for the treatment of depression. It is the active metabolite of fluoxetine, a selective serotonin reuptake inhibitor (SSRI). Seproxetine was being developed as a "me too" drug for the indication of depression and had reached phase II clinical trials before development was discontinued.

Pharmacology[edit | edit source]

Seproxetine, like its parent compound fluoxetine, works by inhibiting the reuptake of serotonin in the brain, thereby increasing levels of this neurotransmitter available to bind to the post-synaptic receptor. It has been shown to be a potent and selective inhibitor of serotonin reuptake, making it a powerful antidepressant.

Development and Clinical Trials[edit | edit source]

Seproxetine was being developed by Eli Lilly and Company, the same company that developed fluoxetine. It had reached phase II clinical trials for the treatment of depression. However, development was discontinued for unknown reasons. It is speculated that the development was stopped due to the emergence of unexpected side effects during the trials, or due to strategic decisions within the company.

See Also[edit | edit source]

References[edit | edit source]


Seproxetine Resources
Wikipedia
WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD